Our Development Pipeline

In addition to our Universal Cancer Vaccine platform, we are also working with UCLA to create two other immunotherapy technologies.

cancer
Children’s Cancer

We have created our first cancer drug candidate – a single-disease specific immunotherapy targeting Ewing sarcoma, a rare but deadly bone and soft tissue cancer primarily affecting children and young adults. Unfortunately, the death rate for patients with recurrent Ewing sarcoma is nearly 100%. ​ ​

Based on the positive data, we plan to launch FDA IND enabling studies needed to apply for approval to proceed with human trials. We look forward to the day when treating cancer will be as simple as getting a flu shot – a better way to treat cancer.

cancer
Universal CAR-T Cell Platform (UCAR-T)

Our UCAR-T Cell platform is a novel and customizable low-cost cancer treatment platform, delivered as a shot, that can reprogram natural immune T-cells inside the body to seek and destroy targeted cancer cells. These modified T-cells are called Chimeric Antigen Receptor (CAR) T Cells. Conventional CAR-T Cell therapy can cost more than $500,000 per dose due to complicated and expensive lab processes. Our goal is to lower the cost to a few thousand dollars per dose by helping the body make its own CAR T cells.  

Our Universal Cancer Vaccine platform and our UCAR-T Cell platform can be used separately, however, when used together, we believe that we can kill cancer cells with extreme precision using the body’s immune system at very low costs. Our Universal Cancer Vaccine platform detects and marks a unique target and our UCAR-T Cell platform makes T-cells that attack that target.

UCV and UCAR-T can be used separately. However, when used together, we can kill cancer cells with extreme precision using the body’s immune system at very low costs. UCV detects and marks a unique target and UCAR-T makes T-cells attack that target.

Massive Market Opportunity

How big is the biotechnology market?

According to Precedence Research, the global biotechnology market is projected to grow from $1.3 trillion in 2023 to $3.2 trillion by 2030

Biotech
$3.2 trillion

How big is the cancer drug development market?

According to Fortune Business Insights, the global oncology drugs market is projected to grow from $205 billion in 2023 to $484 billion by 2030.

Cancer
$484 billion
CancerVax

redefining
immunotherapy

Pre-clinical. We’re developing cutting edge immunotherapy cancer treatments that use the body’s immune system to fight cancer.

World-class researchers and scientists.

Our team of dedicated scientists is on the cutting edge of cancer research. From the lab to the clinic, we are committed to finding new and better ways to prevent and treat cancer.

80

Years of collective
experience

health
CancerVax

Podcast

Thumbnail

November 2, 2023 - Ezra Cohen Tempus Labs

Thumbnail

October 2, 2023 - CancerVax CEO Discusses Expanded Pipeline at UCLA

Thumbnail

August 14, 2023 - Steven Jonas - UCLA

Thumbnail

June 28, 2023 - Lara Sullivan - Pyxis Oncology

News Highlights

April 3, 2024

CancerVax Launches $5 Million Funding Round

CancerVax, Inc., developer of a breakthrough Universal Cancer Vaccine treatment that will use the body’s immune system to fight cancer, today announced that its Reg A+ offering has been qualified by the SEC allowing the Company to formally launch a funding round of up to $5 million. Proceeds from the SEC qualified Reg A+ offering will be used by the Company to continue work on its breakthrough cancer treatments

November 2, 2023

CancerVax CEO Ryan Davies Discusses Cancer Drug Development with Dr. Ezra Cohen

CancerVax, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, and Tempus Labs Chief Medical Officer for Oncology Dr. Ezra Cohen, discussed his time at Tempus Labs, Moores Cancer Center and University of Chicago

September 12, 2023

CancerVax Expands Development Pipeline to Include a Universal CAR-T Cell Platform

CancerVax, Inc., a pre-clinical biotechnology company working with UCLA to develop breakthrough immunotherapy cancer treatments that use the body’s immune system to fight cancer, today announced an expansion of its development pipeline to include a Universal CAR-T Cell Platform that can dramatically lower the cost of CAR-T cell cancer therapies

August 24, 2023

CancerVax CEO Ryan Davies Discussed Cancer Immunotherapy with UCLA Physician-Scientist

CancerVax, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, spoke with and UCLA cancer physician and researcher, Dr. Steven Jonas, about his journey to becoming both a practicing cancer doctor and active cancer researcher